First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G

BACKGROUND: CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific antigen (TSA), and immunosuppressive tumor microen...

Descripción completa

Detalles Bibliográficos
Autores principales: Anna, François, Bole-Richard, Elodie, LeMaoult, Joel, Escande, Marie, Lecomte, Martin, Certoux, Jean-Marie, Souque, Philippe, Garnache, Francine, Adotevi, Olivier, Langlade-Demoyen, Pierre, Loustau, Maria, Caumartin, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978334/
https://www.ncbi.nlm.nih.gov/pubmed/33737343
http://dx.doi.org/10.1136/jitc-2020-001998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978334/
https://www.ncbi.nlm.nih.gov/pubmed/33737343
http://dx.doi.org/10.1136/jitc-2020-001998

Ejemplares similares